72822-12-9

Basic information

• Product Name: Dapiprazole
• Synonyms: DAPIPRAZOLE;Dapitant;3-[2-[4-(2-Methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,5-a]pyridine;Dapiprazole HCl;3-[2-[4-(2-Methylphenyl)-1-piperazinyl]ethyl]-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyridine;1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]-;3-(2-(4-(o-Tolyl)piperazin-1-yl)ethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
• CAS NO: 72822-12-9
• Molecular Formula: C₁₉H₂₇N₅
• Molecular Weight: 325.45
• Product Categories: Pharmaceutical
• Mol File: 72822-12-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 158-160°
• Boiling Point: 538.9 ºC at 760 mmHg
• Flash Point: 279.7 ºC
• Appearance: /
• Density: 1.22 g/cm³
• Vapor Pressure: 1.11E-11mmHg at 25°C
• Refractive Index: 1.658
• CAS DataBase Reference: Dapiprazole(CAS DataBase Reference)
• NIST Chemistry Reference: Dapiprazole(72822-12-9)
• EPA Substance Registry System: Dapiprazole(72822-12-9)

Safety Data

• Hazardous Substances Data: 72822-12-9(Hazardous Substances Data)

Usage

Description

Dapiprazole, also known by its brand name Rev-Eyes, is a pharmaceutical compound with a variety of applications in the medical field. It is characterized by its adrenergic (α-blocking) properties, which allow it to effectively manage certain conditions and symptoms.

Uses

Used in Ophthalmology:
Dapiprazole is used as an antiglaucoma agent for reducing intraocular pressure in patients with glaucoma. Its α-blocking properties help to facilitate the outflow of aqueous humor, thereby lowering the pressure within the eye and reducing the risk of optic nerve damage.
Used in Psychiatry:
In the field of psychiatry, Dapiprazole is utilized as a neuroleptic and psychotropic agent. It is employed in the treatment of various mental health conditions, such as schizophrenia and bipolar disorder, where its α-blocking properties contribute to the regulation of neurotransmitter activity and stabilization of mood.

InChI:InChI=1/C19H27N5/c1-16-6-2-3-7-17(16)23-14-12-22(13-15-23)11-9-19-21-20-18-8-4-5-10-24(18)19/h2-3,6-7H,4-5,8-15H2,1H3

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.